It is time to drop euphemisms like DNA medicines and gene-based medicines. Gene therapy, says Nuala Moran, has made it through to the commercial mainstream.

Scotland is investing £9.5 million of public money in the Swedish stem cell company Cellartis AB to fund an R&D and manufacturing facility in Dundee.

In a rare example of a university tec transfer deal attracting an upfront payment, French pharma company Ipsen paying €1.25 million for a treatment licence.

Europe has staked its future on building a knowledge economy. But once again, a major R&D investment by one of its leading companies is going to the US.

Industry in Europe and elsewhere will need to act in concert to apply the recommendations iof the report into the disastrous TGN 1412 drugs trial.

In the highest value deal yet seen for a preclinical pipeline, GlaxoSmithKline plc swooped on Domantis Ltd, paying £230 million cash for the six-year-old UK Medical Research Council spin out.